THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 MAR 2009 Topic Review Article Review 01. 02. 03. 04. Case Review
The Window of Multiple Sclerosis
THE WINDOW OF MULTIPLE SCLEROSIS The Window of Multiple Sclerosis The Window of Multiple Sclerosis http://www.medimedia.co.kr http://www.merck.co.kr The Window of Multiple Sclerosis E-Mail : inquiry@kimsonline.co.kr Copyright 2009 All rights reserved. No part in this publication may be reproduced, stored in a system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without permission in written form from the publisher. This publication is published by MMK Co., Ltd., under continuing medical education granted from Merck Korea Limited. AP-MK-RB-09-01
The Window of Multiple Sclerosis Vol.2 No.1 MAR 2009
Topic Review CONTENTS Article Review 01. 02. 03. 04. Case Review
TOPIC R E V I E W World Congress on Treatment and Research in Multiple Sclerosis September 17-20, 2008 Montreal, Canada The Window of Multiple Sclerosis Vol.2 No.1 THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS Optic neuritis Transverse myelitis (typically longitudinally extensive) At least 2 of the following 3 supporting criteria: Brain MRI normal or showing nonspecific white matter lesions not meeting radiologic criteria for multiple sclerosis Spinal cord MRI showing lesion extending continuously over 3 or more vertebral segments (longitudinally extensive lesion) NMO-lgG seropositivity TOPIC REVIEW 6 7 Neuromyelitis optica Incomplete/partial forms of neuromyelitis optica Single or recurrent LETM Recurrent optic neuritis with negative brain MRI scan Asian optic-spinal multiple sclerosis Optic neuritis or LETM associated with coexisting systemic autoimmune disease Optic neuritis or LETM associated with distinct neuroimaging patterns such as hypothalamic lesions or periependymal brain lesions Vol.2 No.1
TOPIC R E V I E W THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 A B THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW 8 9 Vol.2 No.1
TOPIC R E V I E W World Congress on Treatment and Research in Multiple Sclerosis September 17-20, 2008 Montreal, Canada The Window of Multiple Sclerosis Vol.2 No.1 13thAnnual meeting of the Americas committee for treatment and research in multiple scerosis 24th congress of the European committee for treatment and research in multiple scerosis 5th congress of the latin American committee for treatment and research in multiple scerosis THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW 10 11 Vol.2 No.1
TOPIC R E V I E W THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW 12 13 Vol.2 No.1
TOPIC R E V I E W THE WINDOW OF MULTIPLE SCLEROSIS Vol.2 No.1 THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS TOPIC REVIEW 14 15 Vol.2 No.1
ARTICLE R E V I E W Defining the natural history 08 MS: the need for complete data and rigorous definitions Confavreux C. Mult Scler 2008;14:289-291. THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS 1. Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008;14:314-324. ARTICLE REVIEW 16 17 2. Tremlett H, Zhao Y, Devonshire V. Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler 2008;14:1142-1143; author reply 1144-1147. Vol.2 No.1
ARTICLE R E V I E W Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis Birnbaum G, Cree B, Altafullah I, et al. Neurology 2008;71:1390-1395. THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS ARTICLE REVIEW 18 19 Vol.2 No.1
ARTICLE R E V I E W Kappos L, Gold R, Miller DH, et al. Lancet 2008;372:1463-72. Efficacy and safety of oral fumarate in patients with relapsingremitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS ARTICLE REVIEW 20 21 Vol.2 No.1
ARTICLE R E V I E W Kopadze T, Kieseier BC, Dobert M, et al. Eur J Neurol 2009;16:409-412. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS ARTICLE REVIEW 22 23 Vol.2 No.1
CASE R E V I E W Q1 A1 THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS REVIEW CASE 24 25 Q2 Vol.2 No.1
CASE R E V I E W A2 THE WINDOW OF MULTIPLE SCLEROSIS
THE WINDOW OF MULTIPLE SCLEROSIS REVIEW CASE 26 27 1. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon b-1a subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504. 2. Thompson, A.J., Benign multiple sclerosis, J Neurol Neurosurg Psychiatry 1999;67:138. 3. Brex PA, Ciccare lli O, O Riordan Jl, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N E ngl J Med 2002;346:158-164. 4. Gold R, Rieckmann P, chang P, Abdalla J; PRISMS Study Group. The long-term safety and tolerability of high-dose interferon b-1a in relapsing -remitting multiple sclerosis: 4-year data from the PRISMS study. European Journal of Neurology 2005;12:649-656. Vol.2 No.1
memo
The Window of Multiple Sclerosis The Window of Multiple Sclerosis THE WINDOW OF MULTIPLE SCLEROSIS QUIZ Vol.2 No.1 MAR 2009 Q1. Q2. Magnetic transfer imaging Diffusion tensor imaging Magnetic resonance spectroscopy The Window of Multiple Sclerosis The Window of MS Quiz Q1. Q2.
Balancing Performance & Safety
The Window of Multiple Sclerosis